High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of toll-like receptor 4

Molecular Medicine

Volumn 18, Issue 12, 2012, Pages 1509-1518

  Bauer, Eileen M ^a   Shapiro, Richard ^a   Zheng, Han ^a   Ahmad, Ferhaan ^a   Ishizawar, David ^a   Comhair, Suzy A ^b   Erzurum, Serpil C ^b   Billiar, Timothy R ^a   Bauer, Philip M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA SMOOTH MUSCLE ACTIN; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY; NUCLEAR PROTEIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CHRONIC HYPOXIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE DELETION; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; LUNG ARTERY PRESSURE; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; PULMONARY HYPERTENSION; PULMONARY VASCULAR REMODELING; RESPIRATORY TRACT PARAMETERS; SYSTOLIC BLOOD PRESSURE;

ADULT; ANIMALS; ANOXIA; ANTIBODIES, NEUTRALIZING; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; HMGB1 PROTEIN; HUMANS; HYPERTENSION, PULMONARY; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; TOLL-LIKE RECEPTOR 4;

EID: 84873509875     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2012.00283     Document Type: Article

References (56)

1. Simonneau G, et al. (2004) Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 43:5S-12S.
2. Humbert M, et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43:13S-24S.
3. Rabinovitch M. (2008) Molecular pathogenesis of pulmonary arterial hypertension. J. Clin. Invest. 118:2372-9.
4. Tuder RM, et al. (2009) Development and pathology of pulmonary hypertension. J. Am. Coll. Cardiol. 54:S3-9.
5. Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. (2007) Pathology of pulmonary hypertension. Clin. Chest Med. 28:23-42, vii.
6. Michelakis ED, Wilkins MR, Rabinovitch M. (2008) Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation. 118:1486-95.
7. Galie N, et al. (2009) A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J. 30:394-403.
8. Macchia A, et al. (2007) A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am. Heart J. 153:1037-47.
9. Bianchi ME. (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81:1-5.
10. Bonaldi T, Langst G, Strohner R, Becker PB, Bianchi ME. (2002) The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding. EMBO J. 21:6865-73.
11. Park JS, et al. (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 290:C917-24.
12. Park JS, et al. (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279:7370-7.
13. Hori O, et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270:25752-61.
14. Sodhi CP, et al. (2010) Toll-like receptor-4 inhibits enterocyte proliferation via impaired betacatenin signaling in necrotizing enterocolitis. Gastroenterology. 138:185-96.
15. Liliensiek B, et al. (2004) Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113:1641-50.
16. Yang H, et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U. S. A. 101:296-301.
17. Bauer EM, Shapiro R, Billiar TR, Bauer PM. (2013) High mobility group box 1 inhibits human pulmonary artery endothelial cell migration via a toll-like receptor 4-and interferon response factor 3-dependent mechanism(s). J. Biol. Chem. 288:1365-73.
18. Bauer EM, et al. (2011) Complement C3 deficiency attenuates chronic hypoxia-induced pulmonary hypertension in mice. PLoS One. 6:e28578.
19. Troseid M, et al. (2012) Circulating levels of HMGB1 are correlated strongly with MD2 in HIV-infection: possible implication for TLR4-signalling and chronic immune activation. Innate Immun. 2012, Oct 15 [Epub ahead of print].
20. Stoetzer OJ, et al. (2012) Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol. 2012, Sep 15 [Epub ahead of print].
21. Hashimoto T, et al. (2012) Circulating highmobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis. 221:490-5.
22. Oktayoglu P, et al. (2012) Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life. Rheumatol. Int. 2012, Nov 10 [Epub ahead of print].
23. Allonso D, et al. (2012) Elevated serum levels of high mobility group box 1 (HMGB1) protein in dengue-infected patients are associated with disease symptoms and secondary infection. J. Clin. Virol. 55:214-9.
24. Chung HW, et al. (2012) Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci. 103:1714-21.
25. Zickert A, et al. (2012) Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res. Ther. 14:R36.
26. Dupire G, Nicaise C, Gangji V, Soyfoo MS. (2012) Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjogren's syndrome. Scand. J. Rheumatol. 41:120-3.
27. Iannone F, et al. (2008) Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann. Rheum. Dis. 67:1121-6.
28. Giaid A, et al. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328:1732-9.
29. Channick RN, et al. (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 358:1119-23.
30. Humbert M, et al. (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 122:156-63.
31. Tuder RM, Groves B, Badesch DB, Voelkel NF. (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am. J. Pathol. 144:275-85.
32. Hassoun PM, et al. (2009) Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 54:S10-9.
33. Dahl M, Chalmers A, Wade J, Calverley D, Munt B. (1992) Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy. J. Rheumatol. 19:1807-9.
34. Friedman DM, Mitnick HJ, Danilowicz D. (1992) Recovery from pulmonary hypertension in an adolescent with mixed connective tissue disease. Ann. Rheum. Dis. 51:1001-4.
35. Minamino T, et al. (2001) Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc. Natl. Acad. Sci. U. S. A. 98:8798-803.
36. Savale L, et al. (2009) Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir. Res. 10:6.
37. Steiner MK, et al. (2009) Interleukin-6 overexpression induces pulmonary hypertension. Circ. Res. 104:236-44.
38. Kumar H, Kawai T, Akira S. (2011) Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30:16-34.
39. Matzinger P. (1994) Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991-1045.
40. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. (2008) HMGB1: endogenous danger signaling. Mol. Med. 14:476-84.
41. Sadamura Y, et al. (2011) The role of high mobility group box1 in monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 183:A3413.
42. Tsung A, et al. (2005) The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201:1135-43.
43. Maroso M, et al. (2010) Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat. Med. 16:413-9.
44. Mittal D, et al. (2010) TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J. 29:2242-52.
45. Levy RM, et al. (2007) Systemic inflammation and remote organ injury following trauma require HMGB1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293:R1538-44.
46. Chen J, et al. (2011) Early interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4. Kidney Int. 80:504-15.
47. Spirig R, et al. (2009) TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells. Mol. Immunol. 46:3178-82.
48. Liu JQ, Zelko IN, Erbynn EM, Sham JS, Folz RJ. (2006) Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). Am. J. Physiol. Lung Cell Mol. Physiol. 290:L2-10.
49. Yang H, et al. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U. S. A. 107:11942-7.
50. Andonegui G, et al. (2005) Platelets express functional Toll-like receptor-4. Blood. 106:2417-23.
51. Katsuoka F, et al. (1997) Type II alveolar epithelial cells in lung express receptor for advanced glycation end products (RAGE) gene. Biochem. Biophys. Res. Commun. 238:512-6.
52. Buckley ST, Ehrhardt C. (2010) The receptor for advanced glycation end products (RAGE) and the lung. J. Biomed. Biotechnol. 2010:917108.
53. Lotze MT, DeMarco RA. (2003) Dealing with death: HMGB1 as a novel target for cancer therapy. Curr. Opin. Investig. Drugs. 4:1405-9.
54. Volz HC, Kaya Z, Katus HA, Andrassy M. (2010) The role of HMGB1/RAGE in inflammatory cardiomyopathy. Semin. Thromb. Hemost. 36:185-94.
55. Nogueira-Machado JA, Volpe CM, Veloso CA, Chaves MM. (2011) HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation. Expert Opin. Ther. Targets. 15:1023-35.
56. Tikellis C, et al. (2008) Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. Am. J. Physiol. Endocrinol. Metab. 295:E323-30.